TrialRMD open2023

Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis.

Alice B Gottlieb et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.